Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification

Current Oncology

M. Narushima¹  T. Ishizuka¹  Y. Tamura¹  S. Tajima¹  I. Yonezawa¹  M. Waki²  R. Onoda¹ 

[1] Shizuoka Saiseikai General Hospital;Hamamatsu University School of Medicine

关键词: angiosarcoma;    mucinous cystadenoma;    surgical resection;    chemotherapy;    gemcitabine;    MYC;   

DOI  :  

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

Angiosarcoma is a rare and aggressive type of sarcoma, and primary angiosarcoma of the ovary is extremely rare. We report the case of a 29-year-old woman who was diagnosed with ovarian angiosarcoma and possible bone metastases. We treated this patient with a gemcitabine-based regimen as postoperative adjuvant chemotherapy, after which she achieved at least 7 years of progression-free survival, an extremely long duration given the aggressive features of this tumour. We retrospectively performed immunohistochemical analyses and fluorescence in situ hybridization to make a pathology diagnosis and to investigate the tumour features. MYC amplification and c-Myc protein overexpression were positively detected. It might be possible to correlate the effectiveness of the gemcitabine-based chemotherapeutic regimen with MYC gene amplification and c-Myc protein overexpression.

【 授权许可】

Unknown